SWEDEN, Oct. 6, 2004 (PRIMEZONE) -- AstraZeneca -- Annual Business Review 2004
Indepth interviews available now on www.cantos.com with Sir Tom McKillop, CEO, and other key executives (LSE:AZN)
As AstraZeneca stages its Annual Business Review 2004 key executives talk about the issues facing the company.
- Sir Tom McKillop gives the latest on Exanta and Crestor as well as AZ's growth products and earnings guidance for the year.
- Jan Lundberg, Head of Global Research, talks about the current pipeline and developments in R&D.
- Brent Vose, Head of Oncology, outlines the strength of his division's portfolio.
- Dr Dong Yin, Vice-President, Strategic Planning and Marketing (China) speaks about the strategy AZ it is pursuing in his region and the opportunities and problems being encountered there.
This programming is available in video, audio and transcript.
It's free to view. All you need to do is register at http://www.cantos.com
Cantos.com is an online financial website where top management of companies address the critical issues facing their businesses.
If you would like to contact us, please email enquiries@cantos.com.